Boston Common Asset Management LLC Lowers Stake in Edwards Lifesciences Corporation $EW

Boston Common Asset Management LLC lessened its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 10.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 135,675 shares of the medical research company’s stock after selling 15,187 shares during the period. Boston Common Asset Management LLC’s holdings in Edwards Lifesciences were worth $10,551,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Rosenberg Matthew Hamilton acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $28,000. True Wealth Design LLC increased its holdings in Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after acquiring an additional 259 shares in the last quarter. NewSquare Capital LLC raised its position in Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after acquiring an additional 134 shares during the period. Rakuten Securities Inc. lifted its holdings in Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares in the last quarter. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Edwards Lifesciences in the third quarter valued at about $30,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 11,340 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total transaction of $971,384.40. Following the sale, the vice president owned 31,870 shares of the company’s stock, valued at approximately $2,729,984.20. This trade represents a 26.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,885,571.40. This trade represents a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 57,824 shares of company stock worth $4,863,323 over the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on EW shares. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday. Wall Street Zen downgraded Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, September 29th. UBS Group reaffirmed a “neutral” rating and issued a $95.00 price target (up from $92.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Piper Sandler reissued an “overweight” rating and issued a $98.00 price objective (up from $95.00) on shares of Edwards Lifesciences in a research note on Tuesday. Finally, Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price on the stock in a research note on Monday, November 3rd. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus price target of $96.82.

Edwards Lifesciences Trading Up 2.0%

Shares of EW opened at $85.12 on Thursday. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The firm has a market capitalization of $49.39 billion, a P/E ratio of 36.69, a P/E/G ratio of 3.18 and a beta of 0.95. The firm has a 50-day moving average price of $85.08 and a 200 day moving average price of $80.72. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the business earned $0.67 earnings per share. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.